<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609218</url>
  </required_header>
  <id_info>
    <org_study_id>12858</org_study_id>
    <secondary_id>H8Y-MC-HBCZ</secondary_id>
    <nct_id>NCT01609218</nct_id>
  </id_info>
  <brief_title>A Study of LY2140023 in Healthy Participants</brief_title>
  <official_title>A Study to Evaluate the Impact of Activated Charcoal on the Absorption of LY2140023 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denovo Biopharma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denovo Biopharma LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of activated charcoal on absorption of LY2140023. The&#xD;
      study involves a single dose of 80 milligrams (mg) LY2140023 taken as 1 tablet by mouth 2&#xD;
      times during study (once with activated charcoal, once without activated charcoal). This&#xD;
      study will last approximately 16 days, not including screening. Screening is required within&#xD;
      28 days prior to study entry.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2140023</measure>
    <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
    <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY2140023 alone and in the presence of aqueous activated charcoal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY2140023</measure>
    <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
    <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY2140023 alone and in the presence of aqueous activated charcoal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY404039 (Active Moiety)</measure>
    <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
    <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY404039 alone and in the presence of aqueous activated charcoal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY404039 (Active Moiety)</measure>
    <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
    <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY404039 alone and in the presence of aqueous activated charcoal.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>80 mg LY2140023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 80 milligrams (mg) LY2140023 administered alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg LY2140023 + 75 g aqueous activated charcoal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 grams (g) aqueous activated charcoal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2140023</intervention_name>
    <arm_group_label>80 mg LY2140023</arm_group_label>
    <arm_group_label>80 mg LY2140023 + 75 g aqueous activated charcoal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aqueous activated charcoal</intervention_name>
    <arm_group_label>80 mg LY2140023 + 75 g aqueous activated charcoal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  are healthy males or females, as determined by medical history and physical&#xD;
             examination&#xD;
&#xD;
          -  male participants agree to use a reliable method of birth control during the study and&#xD;
             for 3 months following the last dose of LY2140023, and agree not to donate sperm for 3&#xD;
             months following the last dose of LY2140023&#xD;
&#xD;
          -  female participants:&#xD;
&#xD;
               -  of childbearing potential, who test negative for pregnancy at screening and who&#xD;
                  agree to use a reliable method of birth control during the study and for 3 months&#xD;
                  following the last dose of LY2140023&#xD;
&#xD;
               -  of non-childbearing potential; postmenopausal or permanently sterile following&#xD;
                  hysterectomy, bilateral salpingectomy or confirmed tubal occlusion (not tubal&#xD;
                  ligation). Postmenopausal is defined as spontaneous amenorrhea for at least 12&#xD;
                  months, and a plasma follicle-stimulating hormone (FSH) level &gt;40&#xD;
                  milli-international units per milliliter(mIU/mL), unless the participant is&#xD;
                  taking hormone replacement therapy&#xD;
&#xD;
          -  have given written informed consent approved by Lilly and the chosen ethical review&#xD;
             board (ERB)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  are currently enrolled in, have completed or discontinued within the last 90 days&#xD;
             from, a clinical trial involving an investigational product other than the&#xD;
             investigational product used in this study; or are concurrently enrolled in any other&#xD;
             type of medical research judged not to be scientifically or medically compatible with&#xD;
             this study&#xD;
&#xD;
          -  have known allergies to LY2140023 or LY404039, related compounds, activated charcoal,&#xD;
             or any components of the formulation&#xD;
&#xD;
          -  are participants who have previously withdrawn from this study or any other study&#xD;
             investigating LY2140023 after receiving at least 1 dose of LY2140023&#xD;
&#xD;
          -  show evidence or any history of significant active neuropsychiatric disease (for&#xD;
             example, manic depressive illness, schizophrenia, depression)&#xD;
&#xD;
          -  have increased risk of seizures based on a history of:&#xD;
&#xD;
               -  one or more seizures (except for a single simple febrile seizure [lacking&#xD;
                  focality and lasting less than 15 minutes, not associated with a central nervous&#xD;
                  system (CNS) infection or severe metabolic disturbance] as a child between ages 6&#xD;
                  months to 5 years)&#xD;
&#xD;
               -  head trauma with loss of consciousness or a post-concussive syndrome within 1&#xD;
                  year or lifetime history of head trauma with persistent neurological deficit&#xD;
                  (focal or diffuse)&#xD;
&#xD;
               -  CNS infection, uncontrolled migraine, or transient ischemic attack (TIA) within 1&#xD;
                  year; stroke with persistent neurological deficit (focal or diffuse).&#xD;
                  Uncontrolled migraine is defined as migraine attacks that produce headache&#xD;
                  lasting up to 72 hours and are often accompanied by associated symptoms (nausea,&#xD;
                  photophobia, and phonophobia) that impair well-being and disrupt social&#xD;
                  functioning. TIA is defined as &quot;mini-stroke&quot; caused by temporary disturbance of&#xD;
                  blood supply to an area of the brain, which results in a sudden, brief decrease&#xD;
                  in brain function&#xD;
&#xD;
               -  CNS infection with persistent neurological deficit (focal or diffuse)&#xD;
&#xD;
               -  brain surgery&#xD;
&#xD;
               -  electroencephalogram (EEG) with paroxysmal (epileptiform) activity (isolated&#xD;
                  spikes waves, repetitive bursts of sharp waves, paroxysmal activity, frank&#xD;
                  seizures, spike-wave complexes, or sharp-slow wave complexes, or as locally&#xD;
                  defined)&#xD;
&#xD;
               -  brain structural lesion, including developmental abnormalities, as determined by&#xD;
                  examination or imaging studies (except hydrocephalus treated by shunt and without&#xD;
                  neurological deficit)&#xD;
&#xD;
          -  show evidence of active renal disease (for example, diabetic renal disease, polycystic&#xD;
             kidney disease) or creatinine clearance less than 90 milliliters per minute (mL/min)&#xD;
             as determined by the Cockroft Gault formula&#xD;
&#xD;
          -  show evidence or any history of known substance dependence or abuse at any time&#xD;
             (according to Diagnostic and Statistical Manual of Mental Disorders [DSM-IV]&#xD;
             diagnosis), or regularly use known drugs of abuse and/or show positive findings on&#xD;
             urinary drug screening&#xD;
&#xD;
          -  have a clinically significant abnormality in the neurological examination&#xD;
&#xD;
          -  participants judged prior to randomization to be at suicidal risk by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <results_first_submitted>August 25, 2021</results_first_submitted>
  <results_first_submitted_qc>August 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2021</results_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a 2-period crossover study. Participants received single doses of LY2140023 on 2 different occasions: 1) LY2140023 administered alone (Treatment A) and 2) LY2140023 administered and followed 1 hour later by a single dose of aqueous activated charcoal (Treatment B). Participants were randomized to Treatment Sequence AB or BA.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>First LY2140023 Alone, Then LY2140023 + Activated Charcoal</title>
          <description>Period 1: Single oral dose of 80 milligrams (mg) LY2140023 administered alone&#xD;
Period 2: Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 grams (g) aqueous activated charcoal&#xD;
There was a washout period of at least 3 days between dosing occasions.</description>
        </group>
        <group group_id="P2">
          <title>First LY2140023 + Activated Charcoal, Then LY2140023 Alone</title>
          <description>Period 1: Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 g aqueous activated charcoal&#xD;
Period 2: Single oral dose of 80 mg LY2140023 administered alone&#xD;
There was a washout period of at least 3 days between dosing occasions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received LY2140023</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Activated Charcoal</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants in this treatment sequence did not receive activated charcoal during Period 1.</participants>
                <participants group_id="P2" count="12">Two participants discontinued after receiving LY2140023 but prior to receiving activated charcoal.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9">One participant did not complete Period 1 but did continue onto Period 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received LY2140023</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Activated Charcoal</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0">Participants in this treatment sequence did not receive activated charcoal during Period 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>This was 2-period crossover study. Participants received single oral doses of LY2140023 on 2 different occasions: 1) 80 mg LY2140023 administered alone (Treatment A) and 2) 80 mg LY2140023 administered and followed 1 hour later by a single oral dose of 75 g aqueous activated charcoal (Treatment B). Participants were randomly assigned to treatment sequence AB or BA.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2140023</title>
        <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY2140023 alone and in the presence of aqueous activated charcoal.</description>
        <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>Participants who received study drug(s), did not have an incidence of vomiting following administration of LY2140023, and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg LY2140023</title>
            <description>Single oral dose of 80 mg LY2140023 administered alone</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2140023 + 75 g Aqueous Activated Charcoal</title>
            <description>Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 g aqueous activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2140023</title>
          <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY2140023 alone and in the presence of aqueous activated charcoal.</description>
          <population>Participants who received study drug(s), did not have an incidence of vomiting following administration of LY2140023, and had evaluable Cmax data.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251" spread="31"/>
                    <measurement group_id="O2" value="171" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY2140023</title>
        <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY2140023 alone and in the presence of aqueous activated charcoal.</description>
        <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>Participants who received study drug(s), did not have an incidence of vomiting following administration of LY2140023, and had evaluable AUC(0-inf) data.</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg LY2140023</title>
            <description>Single oral dose of 80 mg LY2140023 administered alone</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2140023 + 75 g Aqueous Activated Charcoal</title>
            <description>Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 g aqueous activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY2140023</title>
          <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY2140023 alone and in the presence of aqueous activated charcoal.</description>
          <population>Participants who received study drug(s), did not have an incidence of vomiting following administration of LY2140023, and had evaluable AUC(0-inf) data.</population>
          <units>nanogram hours per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1120" spread="24"/>
                    <measurement group_id="O2" value="876" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY404039 (Active Moiety)</title>
        <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY404039 alone and in the presence of aqueous activated charcoal.</description>
        <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>Participants who received study drug(s), did not have an incidence of vomiting following administration of LY2140023, and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg LY2140023</title>
            <description>Single oral dose of 80 mg LY2140023 administered alone</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2140023 + 75 g Aqueous Activated Charcoal</title>
            <description>Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 g aqueous activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY404039 (Active Moiety)</title>
          <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY404039 alone and in the presence of aqueous activated charcoal.</description>
          <population>Participants who received study drug(s), did not have an incidence of vomiting following administration of LY2140023, and had evaluable Cmax data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474" spread="26"/>
                    <measurement group_id="O2" value="324" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY404039 (Active Moiety)</title>
        <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY404039 alone and in the presence of aqueous activated charcoal.</description>
        <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>Participants who received study drug(s), did not have an incidence of vomiting following administration of LY2140023, and had evaluable AUC(0-inf) data.</population>
        <group_list>
          <group group_id="O1">
            <title>80 mg LY2140023</title>
            <description>Single oral dose of 80 mg LY2140023 administered alone</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2140023 + 75 g Aqueous Activated Charcoal</title>
            <description>Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 g aqueous activated charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY404039 (Active Moiety)</title>
          <description>Venous blood samples were collected for pharmacokinetic parameter estimates for LY404039 alone and in the presence of aqueous activated charcoal.</description>
          <population>Participants who received study drug(s), did not have an incidence of vomiting following administration of LY2140023, and had evaluable AUC(0-inf) data.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2780" spread="15"/>
                    <measurement group_id="O2" value="2190" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>80 mg LY2140023</title>
          <description>Single oral dose of 80 mg LY2140023 administered alone</description>
        </group>
        <group group_id="E2">
          <title>80 mg LY2140023 + 75 g Aqueous Activated Charcoal</title>
          <description>Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 g aqueous activated charcoal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

